• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Tuberculosis subunit vaccines: from basic science to clinical testing.
【24h】

Tuberculosis subunit vaccines: from basic science to clinical testing.

机译：结核亚单位疫苗：从基础科学到临床测试。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

More than 80 years after the introduction of Bacillus Calmette-GuErin, the first tuberculosis vaccine, new vaccines for tuberculosis are finally in clinical trials. The selection of antigens on which new subunit vaccines are based represent the first fulfillment of the promise of proteomics and genomics, and the delivery systems for these antigens are likewise the first fruits of the improved understanding of how the host immune system recognizes pathogens. However, clinical trials are still at Phase I and there remain formidable obstacles to the registration of the first new TB vaccines. Here the authors review the vaccines in clinical trials and discuss the different approaches they take to stimulating immunity to Mycobacterium tuberculosis infection, focusing on recombinant subunit vaccines. The challenges that confront these approaches and how they are being addressed are then discussed.
机译：在第一个结核病疫苗卡介苗（Bacillus Calmette-GuErin）问世80多年后，新的结核病疫苗终于在临床试验中。新亚基疫苗所基于的抗原的选择代表了蛋白质组学和基因组学的承诺的首次实现，这些抗原的递送系统同样是对宿主免疫系统如何识别病原体的进一步了解的最初成果。但是，临床试验仍处于第一阶段，首批新的结核病疫苗注册仍然存在巨大的障碍。在这里，作者回顾了临床试验中的疫苗，并讨论了他们针对刺激结核分枝杆菌感染免疫所采取的不同方法，重点是重组亚单位疫苗。然后讨论了这些方法面临的挑战以及如何解决它们。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号